Cyclo Therapeutics, Inc. (CYTH)
|Net Income (ttm)||-8.90M|
|Trading Day||January 22|
|Day's Range||6.02 - 6.32|
|52-Week Range||3.85 - 6.39|
There are no news available yet.
Cyclo Therapeutics, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo ... [Read more...]
N. Scott Fine
|Stock Exchange |
|Ticker Symbol |
In 2019, CYTH's revenue was $1.01 million, a decrease of -0.42% compared to the previous year's $1.01 million. Losses were -$7.53 million, 77.0% more than in 2018.
According to one analyst, the rating for CYTH stock is "Buy" and the 12-month stock price forecast is 12.00.